H Zhang1, J Pang2, Y Zhang2, Y Ma2, F Fan2, H Liu2. 1. School of Clinical Medicine, Bengbu Medical College, Bengbu 233000, China. 2. School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China.
Abstract
OBJECTIVE: To investigate the effects of AZD9291 on the proliferation and migration of nasopharyngeal carcinoma cells. METHODS: Nasopharyngeal carcinoma HNE1 and CNE2Z cells were treated with AZD9291 at the doses of 0.5, 1, 2, 4, and 8 μmol/L and at the doses of 1, 2, 4, 8, and 16 μmol/L, respectively. Cell survival was measured using CCK8 assay, and proliferation inhibition of the cells after AZD9291 treatment was examined with colony-forming assay; the cell repair and migration abilities were determined using scratch assay and Transwell experiment. The expressions of EGFR-related signaling proteins and migration-related proteins were detected using Western blotting. RESULTS: The results of CCK8 assay and colonyforming assay showed that AZD9291 significantly inhibited the viability and proliferation of both HNE1 and CNE2Z cells (P < 0.01). AZD9291 treatment also attenuated the migration ability of HNE1 and CNE2Z cells (P < 0.01). Western blotting showed that, as the concentration of AZD9291 increased, the expression levels of the proteins involved in the PI3K-AKT-mTOR signaling pathway were lowered progressively (P < 0.01), resulting in inhibition of migration of HNE1 and CNE2Z cells (P < 0.01). CONCLUSION: AZD9291 suppresses proliferation and attenuates repair and migration capacities of nasopharyngeal carcinoma cells by inhibiting the EGFR/PI3K/AKT/mTOR signaling pathway, suggesting the potential value of AZD9291 in the treatment of nasopharyngeal carcinoma.
OBJECTIVE: To investigate the effects of AZD9291 on the proliferation and migration of nasopharyngeal carcinoma cells. METHODS: Nasopharyngeal carcinoma HNE1 and CNE2Z cells were treated with AZD9291 at the doses of 0.5, 1, 2, 4, and 8 μmol/L and at the doses of 1, 2, 4, 8, and 16 μmol/L, respectively. Cell survival was measured using CCK8 assay, and proliferation inhibition of the cells after AZD9291 treatment was examined with colony-forming assay; the cell repair and migration abilities were determined using scratch assay and Transwell experiment. The expressions of EGFR-related signaling proteins and migration-related proteins were detected using Western blotting. RESULTS: The results of CCK8 assay and colonyforming assay showed that AZD9291 significantly inhibited the viability and proliferation of both HNE1 and CNE2Z cells (P < 0.01). AZD9291 treatment also attenuated the migration ability of HNE1 and CNE2Z cells (P < 0.01). Western blotting showed that, as the concentration of AZD9291 increased, the expression levels of the proteins involved in the PI3K-AKT-mTOR signaling pathway were lowered progressively (P < 0.01), resulting in inhibition of migration of HNE1 and CNE2Z cells (P < 0.01). CONCLUSION: AZD9291 suppresses proliferation and attenuates repair and migration capacities of nasopharyngeal carcinoma cells by inhibiting the EGFR/PI3K/AKT/mTOR signaling pathway, suggesting the potential value of AZD9291 in the treatment of nasopharyngeal carcinoma.
Authors: Anthony T C Chan; S F Leung; Roger K C Ngan; Peter M L Teo; W H Lau; W H Kwan; Edwin P Hui; H Y Yiu; Winnie Yeo; F Y Cheung; K H Yu; K W Chiu; D T Chan; Tony S K Mok; Stephen Yau; K T Yuen; Frankie K F Mo; Maria M P Lai; Brigette B Y Ma; Michael K M Kam; Thomas W T Leung; Philip J Johnson; Peter H K Choi; Benny C Y Zee Journal: J Natl Cancer Inst Date: 2005-04-06 Impact factor: 13.506
Authors: M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Joseph Wee; Eng Huat Tan; Bee Choo Tai; Hwee Bee Wong; Swan Swan Leong; Terence Tan; Eu Tiong Chua; Edward Yang; Khai Mun Lee; Kam Weng Fong; Hoon Seng Khoo Tan; Kim Shang Lee; Susan Loong; Vijay Sethi; Eu Jin Chua; David Machin Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Anne W M Lee; Stewart Y Tung; Daniel T T Chua; Roger K C Ngan; Rick Chappell; Raymond Tung; Lillian Siu; W T Ng; W K Sze; Gordon K H Au; Stephen C K Law; Brian O'Sullivan; T K Yau; T W Leung; Joseph S K Au; W M Sze; C W Choi; K K Fung; Joseph T Lau; W H Lau Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 13.506
Authors: X Wu; P Y Huang; P J Peng; L X Lu; F Han; S X Wu; X Hou; H Y Zhao; Y Huang; W F Fang; Y Y Zhao; C Xue; Z H Hu; J Zhang; J W Zhang; Y X Ma; W H Liang; C Zhao; L Zhang Journal: Ann Oncol Date: 2013-05-09 Impact factor: 32.976